Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.59 USD
Change Today -0.06 / -3.64%
Volume 44.0K
As of 5:20 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/7/14 - $18.00
52 Week Low
08/4/15 - $1.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

wafergen bio-systems inc (WGBS) Related Businessweek News

No Related Businessweek News Found

wafergen bio-systems inc (WGBS) Details

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. The company offers SmartChip Real-Time PCR system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. The company also provides SmartChip Target Enrichment system for performing a sample preparation step prior to targeted next-generation sequencing (NGS); and Apollo 324TM library preparation System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis and cell biology, primarily at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker discovery and genetic research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California.

49 Employees
Last Reported Date: 05/14/15
Founded in 2002

wafergen bio-systems inc (WGBS) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $77.9K
Compensation as of Fiscal Year 2014.

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Bio-Systems, Inc. Announces Resignation of Keith Warner as Chief Operating Officer

As a result of its determination to eliminate the chief operating officer position, on July 1, 2015, WaferGen Bio-systems, Inc. terminated the employment of Keith Warner effective as of July 15, 2015.

WaferGen Bio-Systems, Inc. Announces Management Changes

WaferGen Bio-systems, Inc. announced that the company has appointed Rolland D. Carlson, President & CEO, effective immediately. Dr. Carlson assumes this role from Ivan Trifunovich who has served as President & CEO of WaferGen since March 2012. Dr. Trifunovich has been appointed Executive Chairman of WaferGen. Most recently, Dr. Carlson served as President & CEO of Asuragen, Inc.

WaferGen Bio-systems, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Full Year 2015

WaferGen Bio-systems, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's product revenue decreased by $260,000, or 20%, as compared to the three months ended March 31, 2014. Total revenue, including license and royalty revenue was $1,146,000, an 18% decrease from $1,406,000 for the three months ended March 31, 2014. The decrease is primarily due to a reduction in sales of SmartChip capital equipment in the three months ended March 31, 2015, with revenue of $102,000, down 83% from the 2014 period, with certain potential customers unable to get their capital expenditure budgets released. Net loss attributable to stockholders was $4.8 million, or $0.85 per basic and diluted share, compared to a net loss of $2.5 million, or $2.79 per basic and diluted share in the first quarter of 2014. Operating loss was $4,574,000 against $2,653,000 a year ago. Net loss before provision for income taxes was $4,804,000 against $2,543,000 a year ago. The company continues to expect full-year 2015 revenue of $8.0 to $8.5 million, which excludes revenue from company's single cell products, presently being developed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $1.59 USD -0.06

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.01 USD +0.03
Exiqon A/S kr13.00 DKK +0.30
HTG Molecular Diagnostics Inc $7.74 USD -0.34
NanoString Technologies Inc $16.12 USD +0.37
Pacific Biosciences of California Inc $5.80 USD +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at